Natco’s Alvogen first to market generic oseltamivir phosphate in US

03 Nov 2017 Evaluate

Natco Pharma’s marketing partner Alvogen has received the final approval and is the first to market the generic equivalent to oseltamivir phosphate, 6 mg/ml powder for oral suspension in the United States. In December 2016, Alvogen launched the first generic equivalent to oseltamivir phosphate capsules in the United States.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

898.80 -34.80 (-3.73%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×